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Abstract
Background: MicroRNA-126 has been found to be consistently under-expressed in osteosarcoma tissues and cell lines
compared with normal bone tissues and normal osteoblast cells, respectively. The purpose of the present study was to
detect the expression levels of miR-126 in osteosarcoma patients and to further investigate the clinicopathological, and
prognostic value of miR-126.
Methods: We recruited 122 patients with osteosarcomas from the Department of Orthopedic Surgery, Yantaishan
Hospital between May 2008 and April 2013. The expression level of miR-126 was determined by qRT-PCR. Associations
between miR-126 expression and various clinicopathological characteristics were analyzed using the χ2 test. Survival
rate was determined with Kaplan-Meier and statistically analyzed with the log-rank method between groups. Survival
data were evaluated through multivariate Cox regression analysis.
Results: miR-126 expression was significantly decreased in osteosarcoma tissues compared to adjacent normal bone
tissues (2.421 ± 1.250 vs. 6.212 ± 1.843, P = 0.001). We found that low miR-126 expression had significant association
with advanced TNM stage (P <0.001), distant metastasis (P <0.001), and higher tumor grade (P = 0.001). Kaplan-Meier
survival analysis showed that the miR-126 low-expression group had significantly shorter overall survival time than
those with high-expression (log-rank test, P = 0.008). Furthermore, multivariate Cox proportional hazards model analysis
showed that miR-126 expression was independently associated with overall survival of patients with osteosarcoma
(HR = 3.102, 95 % CI: 1.113–9.023, P = 0.018).
Conclusions: This is the first study revealing that miR-126 down-expression may be related to the prediction of poor
prognosis for osteosarcoma patients, suggesting that miR-126 may serve as a prognostic marker for the optimization of
clinical treatments.
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Background
Osteosarcoma is one of the most frequent primary skel-
etal neoplasms, second only to plasma cell myeloma, in
children, adolescents and young adults [1]. Though
advances of modern treatments such as surgery, chemo-
therapy, and the combination of surgery and chemother-
apy are improved, long-term survival rate of patients
diagnosed with advanced osteosarcoma remains very low
[2, 3]. Thus, a better understanding of the biology of this
malignancy is necessary to develop novel treatment
strategies.
MicroRNAs (miRNAs) represent small, endogenous,
non-coding RNA molecules with highly conserved se-
quences across species in plants, animals, and DNA
viruses [4]. miRNAs can regulate gene expression at the
posttranscriptional level by binding to the 3′-untrans-
lated regions of their target mRNAs [5]. It has been esti-
mated that miRNAs can regulate as much as 60 % of the
human protein coding genes. miRNAs play crucial roles
in a number of biological processes, such as embryogen-
esis, development, cell maintenance, lineage determin-
ation, cell proliferation, apoptosis and differentiation [6].
In addition, accumulating studies also show that miRNAs
can be dysregulated in various pathological processes, such
as human cancers [7]. They function either as oncogenes* Correspondence: binzhou_liuwei@126.com
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or as tumor suppressors depending on the role of their
target mRNAs [8].
MicroRNA-126 (miR-126) is located on chromosome
9q34.3 within the host gene encoding epidermal growth
factor-like domain 7 (EGFL7) [9]. Previously, miR-126
has been found to be consistently under-expressed in
osteosarcoma tissues and cell lines compared with nor-
mal bone tissues and normal osteoblast cells, respectively
[10, 11]. In the present study, we aimed to investigate the
clinical significance and prognostic value of miR-126 in
osteosarcoma.
Methods
Patients and clinical specimens
This study was approved by the Ethical Review Committee
of Yantaishan Hospital. All specimens were handled
and made anonymous according to the ethical and legal
standards and were obtained with patients’ written in-
formed consent. In total, we recruited 122 patients with
osteosarcomas from Department of Orthopedic Surgery,
Yantaishan Hospital between May 2008 and April 2013.
None of the patients enrolled in this study had received
any chemotherapy or radiotherapy before surgery. Clin-
ical data was collected from the patients’ database of
our institutions. Tumor stage was classified according
to the sixth edition of the TNM classification of the
International Union against Cancer (UICC). For tissue
sample collection, 100 pairs of osteosarcoma tissues
and corresponding noncancerous bone tissues were col-
lected from the same patients. The 100 tissue pairs
were collected for each patient. The tissues were re-
moved from surgical specimens, immediately trans-
ported to the Pathology Laboratory, frozen and stored
at −80 °C for RNA extraction. All tissue samples were
reviewed by two pathologists, and the clinicopathologic
data such as age, sex, site, histological type, tumor
grade were summarized in Table 1.
Quantitative reverse transcriptase PCR (qRT-PCR) assay
The expression of miR-126 in the osteosarcoma and
corresponding non-cancer tissues was determined by
qRT-PCR assay. Briefly, total RNA was extracted from
the tissues using TRIzol reagent (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s protocol.
miRNA expression levels were then quantitated using
the TaqMan miRNA real-time RT-PCR kit (Applied
Biosystems) according to the manufacturer’s protocol.
Data were analyzed using 7500 software v.2.0.1 (Applied
Biosystems), with the automatic Ct setting for adapting
baseline and threshold for Ct determination. The univer-
sal small nuclear RNA U6 (RNU6B) was used as an
endogenous control for miRNAs. Each sample was ex-
amined in triplicate, and the amounts of PCR products
produced were non-neoplasticized to RNU6B. Primers
were synthesized by Sangon Biotech (Shanghai, China),
and the forward primers for miR-126 and U6 were 5′-
tcgtaccgtgagtaataatgcg-3′ and 5′-ctcgcttcggcagcaca-3′,
respectively, while the universal qRT-RCR primer in-
cluded in the One Step PrimeScript® miRNA cDNA
Synthesis Kit (Takara, Japan) was used as the reverse
primer.
Statistical analysis
All quantified data were presented as mean ± SD. Differ-
ences between groups were calculated using Student’s
t test. Associations between miR-126 expression and
various clinicopathological characteristics were analyzed
using the χ2 test. Survival times were counted from the
date of presentation to the date of death or last follow-
up time. Survival rate was determined with Kaplan-
Meier and statistically analyzed with the log-rank
method between groups. Survival data were evaluated
through multivariate Cox regression analysis. All P-values
were determined from 2-sided tests, and statistical signifi-
cance was based on a P-value of 0.05. All statistical
Table 1 Association of miR-126 expression with clinicopathological
features of osteosarcoma
miR-126 expression
Variables Cases (n) Low (n = 60) High (n = 62) P value
Age (years)
<18 54 29 25 0.466
≥18 68 31 37
Gender
Male 78 37 41 0.707
Female 44 23 21
Location
Proximal 72 33 39 0.462
Distal 50 27 23
TNM stage
I + II 81 29 52 <0.001
III + IV 41 31 10
Distant metastasis
Yes 36 28 8 <0.001
No 86 32 54
Histological type
Osteoblastic 55 28 27 0.527
Chondroblastic 32 16 16
Fibroblastic 27 12 15
Telangiectatic 8 4 4
Tumor grade
Low 55 18 37 0.001
High 67 42 25
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analyses were performed using the SPSS 18.0 software
(SPSS, Chicago, IL).
Results
miR-126 is down-expressed in osteosarcoma tissues
qRT-PCR was used to measure miR-126 expression
levels in a total of 122 patients with osteosarcoma. miR-
126 expression was significantly decreased in clinical
osteosarcoma tissues compared to adjacent normal bone
tissues (2.421 ± 1.250 vs. 6.212 ± 1.843, P = 0.001, shown
in Fig. 1).
Correlation between miR-126 expression and
clinicopathologic features in patients with osteosarcoma
The patients with osteosarcoma were classified into
two groups based on the median value (2.06) of rela-
tive miR-126 expression. The association between
miR-126 expression and clinico-pathologic features in
patients with osteosarcoma was analyzed using chi-
square test. As shown in Table 1, low miR-126 ex-
pression showed significant association with advanced
TNM stage (P <0.001), distant metastasis (P <0.001),
and higher tumor grade (P = 0.001), but no significant as-
sociation with patient’s age (P = 0.466), gender (P = 0.707),
location (P = 0.462), and histological type (P = 0.527).
Taken together, these results indicated that down-
expressed miR-126 was correlated with the progres-
sion and development of osteosarcoma.
Correlation between miR-126 expression and prognosis in
patients with osteosarcoma
Kaplan-Meier survival analysis data showed that the
miR-126 low-expression group had significantly shorter
overall survival time than those with high-expression
(log-rank test, P = 0.008, shown in Fig. 2). Univariate and
multivariate analyses were utilized to evaluate whether
the miR-126 expression level and various clinicopatho-
logical features were independent prognostic parameters
of osteosarcoma patient outcomes. Multivariate Cox
proportional hazards model analysis showed that miR-
126 expression was independently associated with over-
all survival of patients with osteosarcoma (HR = 3.102,
95 % CI: 1.113–9.023, P = 0.018, shown in Table 2), indi-
cating that miR-126 could be an independent prognostic
factor of overall survival for patients with osteosarcoma.
Discussion
Osteosarcoma, mainly arising from the metaphysis of
the long bones, is the most common primary malig-
nancy of bone in adolescents and young adults, with an
estimated worldwide yearly incidence rate of 4 million
[12, 13]. Despite current therapeutic strategies combin-
ing adjuvant chemotherapy, surgery and sometimes
radiotherapy, the prognosis of osteosarcoma patients
remains poor, since ~80 % of patients eventually develop
recurrent metastatic osteosarcoma following surgical
treatment, and the 5-year survival rate of these patients
is only 50-60 % [14, 15]. To date, there are no estab-
lished available biomarkers routinely used to predict the
therapeutic outcomes of osteosarcoma reliably. Conse-
quently, exploring more specific prognostic biomarkers
to stratify individuals with poor prognosis to benefit
from multimodal therapy effectively is an imperative
need for advancing the rapeutic strategies for osteosar-
coma patients.
Emerging evidence suggests that gene dysregulation,
including protein-coding genes, microRNA, and long
non-coding RNAs, may affect cellular growth advantage,
resulting in progressive and uncontrolled tumor growth
and metastasis [16–18]. Effective control of both cell
proliferation and cell invasion is critical to the preven-
tion of tumorigenesis and to successful cancer therapy.
MiRNAs have been found to be localized to genomic
fragilesites and involved in cancer development and pro-
gression [19, 20]. Therefore, identification of cancer-
associated miRNAs and investigation of their clinical
significance and functions may provide a new perspec-
tive on the cancer therapy.
MiR-126 is frequently downregulated in a variety of
malignancies and acts as a potential tumor suppressor
[21–24]. Moreover, low expression of miR-126 has been
correlated with poor prognosis in several types of cancer,
such as breast cancer, adult T-cell leukemia, and malig-
nant mesothelioma [25–27]. Previously, Xu et al. found
that expression level of miR-126 was reduced in osteo-
sarcoma tissues in comparison with the adjacent normal
tissues. The enforced expression of miR-126 was able to
inhibit cell proliferation in U2OS and MG63 cells, while
miR-126 antisense oligonucleotides (antisense miR-126)
promoted cell proliferation. At the molecular level, their
Fig. 1 The relative expression of miR-126 in 122 paired human
osteosarcoma tissues and their corresponding normal samples
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results further revealed that expression of Sirt1, a mem-
ber of histone deacetylase, was negatively regulated by
miR-126. Their data demonstrated that miR-126 was an
important regulator in osteosarcoma [10]. In the study
by Yang et al., ectopic expression of miR-126 inhibited
cell proliferation, migration and invasion, and induced
apoptosis of MG-63 cells. Moreover, bioinformatic pre-
diction suggested that the sex-determining region Y-box
2 (Sox2) was a target gene of miR-126. Using mRNA
and protein expression analysis, luciferase assays and
rescue assays, they demonstrated that restored expres-
sion of Sox2 dampened miR-126-mediated suppression
of tumor progression, which suggested the important
role of miR-126/Sox2 interaction in tumor progression.
Taken together, their data indicated that miR-126 func-
tioned as a tumor suppressor in osteosarcoma, which
exerted its activity by suppressing the expression of Sox2
[28]. However, until now, the clinical significance and
prognostic value of miR-126 in osteosarcoma have not
been investigated. In the present study, qRT-PCR was
used to measure miR-126 expression levels in a total of
122 patients with osteosarcoma. We found that miR-126
expression was significantly decreased in clinical osteo-
sarcoma tissues compared to adjacent normal bone
tissues. Low miR-126 expression showed significant as-
sociation with advanced TNM stage, distant metastasis,
and higher tumor grade. Kaplan-Meier survival analysis
data showed that the miR-126 low-expression group had
significantly shorter overall survival time than those with
high-expression. Then univariate and multivariate ana-
lyses were utilized to evaluate whether the miR-126 ex-
pression level and various clinicopathological features
were independent prognostic parameters of osteosar-
coma patient outcomes. Multivariate Cox proportional
Fig. 2 Relationship between miR-126 expression and overall survival time
Table 2 Univariate and multivariate analyses for prognostic factors
Univariate analysis Multivariate analysis
Variable Hazard ratio 95 % CI P value Hazard ratio 95 % CI P value
Sex 0.633 0.462–2.192 0.671 0.781 0.369–1.921 0.762
Age 1.782 0.611–5.829 0.429 1.563 0.673–4.826 0.315
Location 0.881 0.628–5.921 0.317 0.682 0.291–3.267 0.665
Histological type 0.567 0.223–1.982 0.312 0.775 0.478–1.289 0.583
Distant metastasis 3.091 1.982–12.221 0.011 3.558 2.182–12.673 0.005
TNM stage 2.918 1.723–9.273 0.014 3.271 1.923–10.882 0.007
Tumor grade 1.982 1.132–10.923 0.038 2.376 1.234–8.923 0.012
miR-126 expression 2.234 1.012–6.912 0.043 3.102 1.113–9.023 0.018
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hazards model analysis showed that miR-126 expression
was independently associated with overall survival of
patients with osteosarcoma, indicating that miR-126
could be an independent prognostic factor of overall
survival for patients with osteosarcoma.
Conclusion
In conclusion, this is the first study revealing that miR-
126 down-expression may be related to the prediction of
poor prognosis for osteosarcoma patients, suggesting
that miR-126 may serve as a prognostic marker for the
optimization of clinical treatments.
Competing interests
There are no potential conflicts of interest.
Authors’ contributions
LW designed the study, carried out the experiments and drafted the
manuscript; ZZY, SL, and YWD participated in the experiments and data
analysis. All authors read and approved the final manuscript.
Author details
1College of Basic Medicine, Binzhou Medical University, No. 346 Guanhai
Road, Laishan District, Yantai 264003, Shandong, China. 2Department of
orthopedics, Yantaishan Hospital, Yantai 264000, Shandong, China.
Received: 26 November 2014 Accepted: 17 June 2015
References
1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: a cancer journal
for clinicians. 2014;64(1):9–29.
2. Leary SE, Wozniak AW, Billups CA, Wu J, McPherson V, Neel MD, et al.
Survival of pediatric patients after relapsed osteosarcoma: the St. Jude
Children’s Research Hospital experience. Cancer. 2013;119(14):2645–53.
3. Kager L, Zoubek A, Kastner U, Kempf-Bielack B, Potratz J, Kotz R, et al. Skip
metastases in osteosarcoma: experience of the Cooperative Osteosarcoma
Study Group. Journal of clinical oncology: official journal of the American
Society of Clinical Oncology. 2006;24(10):1535–41.
4. Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O, et al.
Identification of hundreds of conserved and nonconserved human
microRNAs. Nat Genet. 2005;37(7):766–70.
5. Sassen S, Miska EA, Caldas C. MicroRNA: implications for cancer. Virchows
Archiv : an international journal of pathology. 2008;452(1):1–10.
6. Maire G, Martin JW, Yoshimoto M, Chilton-MacNeill S, Zielenska M,
Squire JA. Analysis of miRNA-gene expression-genomic profiles reveals
complex mechanisms of microRNA deregulation in osteosarcoma. Cancer
genetics. 2011;204(3):138–46.
7. Baumhoer D, Zillmer S, Unger K, Rosemann M, Atkinson MJ, Irmler M, et al.
MicroRNA profiling with correlation to gene expression revealed the
oncogenic miR-17-92 cluster to be up-regulated in osteosarcoma. Cancer
genetics. 2012;205(5):212–9.
8. Jones KB, Salah Z, Del Mare S, Galasso M, Gaudio E, Nuovo GJ, et al. miRNA
signatures associate with pathogenesis and progression of osteosarcoma.
Cancer Res. 2012;72(7):1865–77.
9. Schmidt M, Paes K, De Maziere A, Smyczek T, Yang S, Gray A, et al. EGFL7
regulates the collective migration of endothelial cells by restricting their
spatial distribution. Development. 2007;134(16):2913–23.
10. Xu JQ, Liu P, Si MJ, Ding XY. MicroRNA-126 inhibits osteosarcoma cells
proliferation by targeting Sirt1. Tumour biology: the journal of the
International Society for Oncodevelopmental Biology and Medicine.
2013;34(6):3871–7.
11. Jiang L, He A, Zhang Q, Tao C. miR-126 inhibits cell growth, invasion, and
migration of osteosarcoma cells by downregulating ADAM-9. Tumour Biol.
2014;35(12):12645–54.
12. Teicher BA. Searching for molecular targets in sarcoma. Biochem Pharmacol.
2012;84(1):1–10.
13. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates
from 1973 to 2004: data from the Surveillance, Epidemiology, and End
Results Program. Cancer. 2009;115(7):1531–43.
14. Gorlick R. Current concepts on the molecular biology of osteosarcoma.
Cancer Treat Res. 2009;152:467–78.
15. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances
for pediatric osteosarcoma. Oncologist. 2004;9(4):422–41.
16. Zhu XC, Dong QZ, Zhang XF, Deng B, Jia HL, Ye QH, et al. microRNA-29a
suppresses cell proliferation by targeting SPARC in hepatocellular carcinoma.
International journal of molecular medicine. 2012;30(6):1321–6.
17. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al.
Long non-coding RNA HOTAIR reprograms chromatin state to
promote cancer metastasis. Nature. 2010;464(7291):1071–6.
18. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, et al.
Identification and validation of oncogenes in liver cancer using an integrative
oncogenomic approach. Cell. 2006;125(7):1253–67.
19. Gregory RI, Shiekhattar R. MicroRNA biogenesis and cancer. Cancer Res.
2005;65(9):3509–12.
20. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, et al.
MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic
leukemias. Proc Natl Acad Sci U S A. 2004;101(32):11755–60.
21. Xu L, Li M, Wang M, Yan D, Feng G, An G. The expression of microRNA-375
in plasma and tissue is matched in human colorectal cancer. BMC Cancer.
2014;14:714.
22. Li X, Wang F, Qi Y. MiR-126 inhibits the invasion of gastric cancer cell in part
by targeting Crk. European review for medical and pharmacological sciences.
2014;18(14):2031–7.
23. Liu LY, Wang W, Zhao LY, Guo B, Yang J, Zhao XG, et al. Mir-126 inhibits
growth of SGC-7901 cells by synergistically targeting the oncogenes PI3KR2
and Crk, and the tumor suppressor PLK2. Int J Oncol. 2014;45(3):1257–65.
24. Jia AY, Castillo-Martin M, Bonal DM, Sanchez-Carbayo M, Silva JM,
Cordon-Cardo C. MicroRNA-126 inhibits invasion in bladder cancer via
regulation of ADAM9. Br J Cancer. 2014;110(12):2945–54.
25. Vergho DC, Kneitz S, Kalogirou C, Burger M, Krebs M, Rosenwald A, et al.
Impact of miR-21, miR-126 and miR-221 as prognostic factors of clear cell
renal cell carcinoma with tumor thrombus of the inferior vena cava. PLoS
One. 2014;9(10), e109877.
26. Kim MK, Jung SB, Kim JS, Roh MS, Lee JH, Lee EH, et al. Expression of
microRNA miR-126 and miR-200c is associated with prognosis in patients
with non-small cell lung cancer. Virchows Archiv: an international journal of
pathology. 2014;465(4):463–71.
27. Vergho D, Kneitz S, Rosenwald A, Scherer C, Spahn M, Burger M, et al.
Combination of expression levels of miR-21 and miR-126 is associated with
cancer-specific survival in clear-cell renal cell carcinoma. BMC Cancer.
2014;14:25.
28. Yang C, Hou C, Zhang H, Wang D, Ma Y, Zhang Y, et al. miR-126 functions
as a tumor suppressor in osteosarcoma by targeting Sox2. Int J Mol Sci.
2014;15(1):423–37.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Liu et al. Diagnostic Pathology  (2015) 10:116 Page 5 of 5
